**Incidence of Cancer and Risk Factors for Complication by Cancer in IgG4-Related Sclerosing Cholangitis**

TAKAYOSHI NISHINO  Dept. of Gastroenterology, Tokyo Women's Medical University, Yachiyo Medical Center
MOTOYASU KAN    Dept. of Gastroenterology, Tokyo Women's Medical University, Yachiyo Medical Center
TETSUYA HAMANO   Dept. of Gastroenterology, Tokyo Women's Medical University, Yachiyo Medical Center

**Objectives:**
IgG4-related sclerosing cholangitis (IgG4-SC) is a biliary IgG4-related disease (IgG4-RD) that is characterized by an elevated serum IgG4 concentration and by extensive fibrosis and dense infiltration of the bile duct wall by IgG4-positive plasma cells. There are increasing reports of cancer as a complication of IgG4-RD. We prospectively investigated the incidence of cancer in IgG4-SC patients and attempted to identify risk factors for developing cancer in IgG4-SC.

**Method:**
We divided 48 IgG4-SC patients (M:F = 38:10, mean age 67 years old, median observation period 5.2 years) into two groups: a group with cancer (Group A, n=14) and a group without cancer (Group B, n=34). IgG4-SC was diagnosed according to the clinical diagnostic criteria for IgG4-SC proposed in 2012 (J Hepatobiliary Pancreat Sci 2012). The organs affected by IgG4-SC (more than one organ in some cases) were biliary tract in all 48 cases, pancreas (type 1 AIP) in 46 cases, a salivary gland in 19 cases, the respiratory tract in 10 cases, and a retroperitoneal organ (kidney and/or retroperitoneal fibrosis) in the 10 cases. To determine the relative risk of cancer in IgG4-SC patients, we calculated standardized incidence ratios (SIR) from the national cancer rates in Japan during the observation period.

**Results:**
A total of 16 cancers were diagnosed in 14 of the 48 IgG4-SC patients. The prevalence of cancer in the IgG4-SC patients was 29.1%, and their SIR risk of cancer was 4.5 (95%CI=2.7-7.6, p__0.0001). The cancer sites were the stomach, lung and colon in 3 cases each, the pancreas in 2 cases, and the esophagus, duodenum, thyroid gland, live and urinary bladder in 1 case each. 2. Five of the 16 cancers were detected within one year after the diagnosis of IgG4-SC. The SIR of cancer was 7.8 (CI =3.1-19.6) in the first year after the diagnosis of IgG4-SC and 3.8 (CI=2.1-7.0) thereafter. 3. The results of multivariate analysis showed that the presence of retroperitoneal organ involvement was significant risk factors for developing cancer in IgG4-SC patients (p=0.04), and the serum IgG4 level and whether treated with a steroid were not significant risk factors.

**Conclusions:**
IgG4-SC patients were found to be at increased risk of developing cancer. The possibility of complication by cancer should be borne in mind when treating IgG4-SC patients in whom multiple organs are affected, especially when there is retroperitoneal involvement.